Skip to content

Versi Retriever Approving Trial in Japan

Multi Center, Prospective, Registry Trial of Versi Retriever Mechanical Thrombecomy for Acute Ischemic Stroke in Japan

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04129203
Enrollment
58
Registered
2019-10-16
Start date
2019-02-01
Completion date
2021-12-31
Last updated
2020-11-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stroke, Acute

Keywords

acute ischemic stroke

Brief summary

This is Versi Retriever mechanical thrombectomy device approving study in Japan. Multi center, single arm, prospective registry trial. Physicians control trial, conducted my N Sakai, Kobe City Medical Center General Hospital.

Detailed description

This is Versi Retriever mechanical thrombectomy device approving study in Japan. Multi center, single arm, prospective registry trial. Physicians control trial, conducted my N Sakai, Kobe City Medical Center General Hospital. 60 cases will be enrolled and 90 days follow up need. Primary endpoint is favorable clinical outcome, mRS 0-2. Secondary endpoint are mortality in 90days, immediate successful recanalization, TICI 2b-3, symptomatic intracranial hemorrhage, and any adverse event related to device and or procedure.

Interventions

DEVICEVersi Retriever thrombectomy

Mechanical thrombectomy using Versi Retriever

Sponsors

Kobe City General Hospital
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
20 Years to 85 Years
Healthy volunteers
No

Inclusion criteria

* acute onset neurological sympto m related to occluded vessel * within 8 hours from onset to tre atment or within 24 hours from onset to treatment with imaging diagnosis * contra-indication or failed to int ravenous rt-PA * accessible occlusion at ICA, MC A, VA, BA, PCA * 5-30 of NIHSS * 0-2 of mRS before onset * obtain documented informed co ntent

Exclusion criteria

* following condition; arterial diss ection, engird, inaccessible turtuousity, difficult access by 50% or m ore stenosis, acute intracranial hemorrhage, space occuping lesion or brain tumor, major early ischemic change in brain * occlude 2 major vessel territory * allege for contrast media, * abnormal PTT/APTT within 4 h ours intravenous heparin * hemorrhagic tendency or 3 or more INR with Warfarin administration * 30000cc or less of Platelet * 50mg/dL or less of blood sugar * uncontrolled blood pressure, 185mmHg or more at systolic, 110m mHg or more at diastolic * 90days or less life expancy * pregnant or lactating * join another trial of medicine or medical device * ineligible for trial

Design outcomes

Primary

MeasureTime frameDescription
Good clinical outcome90days after proceduremodified Rankin Score is 0-2

Secondary

MeasureTime frameDescription
Successful recanalizationat 3 passes of device in the procedureTICI 2b-3
Symptomatic and asymptomatic intracranial hemorrhageat 24 hours after procedureNIHSS 4 or more worsened
Good clinical outcome 290days after proceduremRS 0-2 or NIHSS 10 or more improvement
sever advers event90days after proceduredevice or procedure related

Countries

Japan

Contacts

Primary ContactNobuyuki Sakai, MD DMSc
n.sakai@siren.ocn.ne.jp81783024321
Backup ContactChiaki Sakai, MD PhD
chiakimk@cronos.ocn.ne.jp81783024321

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026